Humana
✦ Quant Fair Value how this is computed
- Implied fair-value range of 163.72-283.78, from this stock's own trailing 5-year average P/E applied to trailing EPS.
- Current price is +74.3% above the average-multiple fair value of 223.75.
Valuation each multiple against its own 5-year range
Vs. peers Healthcare Plans
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Humana (HUM) | 46.84B | 38.05 | 2.49 | 0.68% |
| UnitedHealth (UNH) | 304.51B | 19.40 | 3.10 | 2.67% |
| CVS Health (CVS) | 103.43B | 9.39 | 1.28 | 3.29% |
| Elevance Health (ELV) | 85.23B | 16.75 | 1.91 | 1.74% |
| Cigna Group (CI) | 71.38B | 11.94 | 1.65 | 2.28% |
| Centene (CNC) | 31.58B | 21.92 | 1.42 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 28.7% below Morningstar's fair value estimate.
Analyst note
On Nov. 13, the Centers for Medicare and Medicaid Services delayed the implementation of new Medicaid work requirements by six months. Then, on Nov. 16, CMS highlighted overpayment estimates in Medicare Advantage. Covered MCO shares fell 8% on average from the close on Nov. 13 through Nov. 18.
Why it matters: The first new managed care organization policy looks like a mild positive for Medicaid-focused insurers like Centene, Elevance, and Molina. However, the second policy looks negative for Medicare Advantage-focused insurers like UnitedHealth, Humana, and CVS. Based on the slight delay in implementing work requirements in Medicaid, we do not expect to materially change any fair values on our list on that news. The Medicare Advantage story is a bit more complicated, as CMS merely announced the total overpayment estimates in recent years, not how much it intends to claw back from each Medicare Advantage insurer. Since we have already included potential clawbacks and lower ongoing margins in MA in our MCO models since May 2025, we do not intend to change our cash flow estimates at this time.
The bottom line: While we are not changing any fair value estimates currently on the managed care companies that we cover, we recognize the elevated uncertainty that these companies face due to ongoing regulatory scrutiny, like the new potential MA clawbacks on deck. For perspective, our Morningstar Uncertainty Ratings on the MCOs are currently about one notch higher than typical due to potentially negative regulations, like current scrutiny on MA risk assessments. However, since May 2025, we have included substantial cash outflows in our models for each insurer with Medicare Advantage exposure related to potential clawbacks being teed up by this announcement. At that time, we also lowered our long-term margin target in MA due to the potential for lower risk-related payments.
BLANK PAGEHowever, we recognize that the assessed fines may wind up being higher than we currently estimate. For example, based on the estimated overpayments and market share data in MA, we estimate that UnitedHealth may be subject to a roughly $35 billion clawback from years 2018-26 versus the $20 billion we currently estimate in our model. However, that potentially higher clawback would not meet the 5% materiality threshold to change our fair value estimate on UnitedHealth, assuming no other potential changes to our expectations.
Using a similar approach, the valuations of Elevance, Centene, Cigna, and Molina would not be materially affected by such a clawback.
More negatively, Humana's fair value estimate could decline more than 20% in such a scenario, which would put its fair value estimate more in line with recent share prices. Also, depending on its financing needs and timing related to this potential outflow, the company may run into debt covenant challenges. So its shares could be especially volatile, given its exposure to this concern.
Also, CVS recently announced a settlement with CMS on this topic for most of the timeframe highlighted. We assume that a recent settlement with CMS eliminated the vast majority of its liability. If we are incorrect in that assumption, though, CVS' fair value estimate could face up to a high-single-digit percentage cut to its fair value estimate.
Our assumption that fines will be roughly assessed by market share in Medicare Advantage in the above scenario may be incorrect, too, as there may be bad actors in risk assessments in MA. For example, an October 2024 Office of Inspector General report suggested UnitedHealth accounted for roughly half of all inappropriate risk assessments in the studied group, or roughly double its MA market share. If that is correct, UnitedHealth's financial liability could roughly triple from what is in our current model (and cause a mid-single-digit percentage decline in its fair value) from what is in our current model. In that scenario, other MA insurers (the less egregious actors) may face lower financial liabilities than we currently estimate.
For more details on the managed care organizations, including the industry's growth prospects, moat ratings, moat sources, and regulatory concerns like potential MA risk assessment-related clawbacks, please see our September 2026 report, "Industry Landscape: Managed Care Organizations."
Fair value
We are increasing our fair value estimate to $502 per share from $350 per share to reflect the firm's higher profit prospects after a favorable change in its Medicare Advantage star ratings.
We continue to expect 2026 to be a trough year for the firm's profits. After that, though, we expect Humana's profit prospects to materially improve. Specifically, we assume revenue growth of 8% compounded annually through the five years ended in 2031, but as Medicare Advantage margins rise closer to long-term targets and total operating margins return to the mid-3s, we think adjusted EPS can exceed 35% annually through 2031.
Operationally, most of the company's membership growth will likely come from its fully insured business, particularly its Medicare Advantage business, which could have a disproportionate impact on results. While still one of the fastest-growing end markets in medical insurance, Medicare Advantage has faced substantial headwinds that cut into Humana's profits in recent years. However, we expect operating margins to return to more acceptable levels as the elevated utilization is balanced by more attractive plan designs, a better operating structure, and a rebound in its currently weak MA star ratings.
Economic moat
Humana earns a Narrow Morningstar Economic Moat Rating, which reflects its top-tier position in the US private health insurance market. Like many of its peers, Humana benefits from cost advantages, although its focus on Medicare-related plans makes it unique in an industry where intangible assets appear more important than in other medical insurance niches. We do not recognize intangible assets as a companywide moat source, however. Overall, with its ongoing competitive advantages in the US health insurance industry, we expect Humana to typically produce economic profits above capital costs during the next 10 years, although ongoing challenges in the Medicare Advantage market may make that more difficult than usual in the near term.
Medicare Advantage Leadership Keeps Humana's Moat Rating in Narrow Territory
Humana’s cost advantages relate primarily to scale in government programs like Medicare Advantage. For example, Humana enjoys the number-two position in Medicare Advantage, behind only UnitedHealth. Humana is typically the number-one or -two Medicare Advantage insurer in the counties in which it offers plans, and Medicare Advantage enrollment share can rise closer to 1 out of every 3 in its core local markets. This local scale creates negotiating power over local service providers that cater to seniors in this end market, which we think contributes to its cost advantage over most Medicare Advantage peers.
In Medicare Advantage, the government aims to pay insurers like Humana roughly the same amount as the traditional Medicare program to provide benefits for seniors on a risk-adjusted basis. Then, the insurer needs to lower the costs associated with caring for users by making them healthier to provide additional benefits (dental, vision, pharmacy, and so on) while also generating a profit. Within this framework, insurers like Humana need specialized expertise in managing the needs of seniors to improve their health outcomes and ultimately lower costs. Humana has built up this expertise over decades, which generally helps it create a better experience for end users from beginning to end and contributes to intangible assets specifically in that end-user-controlled market.
With its focus on making the complex healthcare system simpler and driving better health outcomes for end users, Humana typically leads the health insurers that we cover in terms of customer satisfaction, which we believe creates a brand-related intangible asset in this end market. In the consumer-driven Medicare Advantage market, factors like brand and differentiated benefits play a strong role for decision-makers because MA plans are sold directly to end users rather than through intermediaries, like employers, in most of the industry. Also, in Medicare Advantage, the government pays insurers bonuses related to star ratings achieved by each insurance plan (1 being the worst and 5 being the best) on measures of outcomes, processes, patient experience, and access. Typically, Humana stands out positively in terms of star ratings, too, scoring well above peers in 2019-24 ratings. However, MA star ratings in 2025-26 remain significantly below what Humana typically produces based on higher regulatory cutoff standards under Democrats and weaker-than-expected scores on certain aspects like its phone center operations. These lower star ratings cut into Humana's marketing in 2025 and bonus payments in 2026. However, in the long run, we expect Humana to improve its star ratings, with a particular focus in one plan where membership is highly concentrated.
Noninsurance Markets Are Not Additive, but Not Destructive, to Humana's Moat
While probably not moatworthy on a stand-alone basis, in our opinion, Humana's ownership of the fourth-largest pharmacy benefit manager and its growing presence in the provider space (primary care facilities and at-home health) help support the outcomes and cost management needed to run successful health insurance plans. Through both direct ownership and partnerships, Humana remains at the forefront of encouraging value-based offerings to boost health outcomes and better manage costs. Management continues to push members toward full-risk arrangements with providers, which could lead to higher profits for Humana and better health outcomes for patients than those in unaligned provider relationships, too.
Regulatory Concerns Create Potential Headwinds for Humana
Our moat rating for Humana is informed by an analysis of potential changes to the US healthcare system, which is the key environmental, social, and governance risk that Humana faces, in our opinion, as efforts to achieve universal coverage may continue. During the next 10 years, we view scenarios where Humana profitably provides medical and pharmaceutical benefits primarily through government programs, such as Medicare Advantage and Medicaid managed care plans, as more likely than not. Also, we expect its economic profits to rebound once it turns around its Medicare Advantage business in the intermediate term, even in a negative regulatory scenario that includes substantial but manageable clawbacks.
Bull case
With its prowess in Medicare Advantage plans, Humana looks likely to benefit from strong demographic trends and increasing popularity of that program in the long run.
Humana enjoys industry-leading customer satisfaction metrics that positively influence its brand and reputation in the consumer-driven Medicare Advantage and Medicaid insurance sectors.
Humana's growth trajectory could rebound from current weakness, with management calling for pretax profits to more than double from 2025 to 2028 and grow in the low double digits in the long run at its June 2025 investor day.
Bear case
Healthcare policy changes may remain a key threat to private insurers like Humana for the foreseeable future.
With its relatively concentrated operations, any missteps in its target markets could have an amplified effect on Humana's bottom line relative to peers.
Humana's top market—Medicare Advantage—appears to be under regulatory scrutiny to curb abuses. Margin pressure, fines, and meager rates notices all appear possible in the short and long run.
By Julie Utterback, CFA
Quote time 2026-11-20 20:01:19 · For reference only, not investment advice and not tailored to your situation.
Humana discussion 0 comments